France Battles Mediterranean Wildfires as Heatwave Fuels Fire Risk 
FDA Investigates New Cyclospora Outbreak as U.S. Cases Continue to Rise 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
UNAIDS Urges U.S. to Reconsider South Africa HIV Funding Withdrawal 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
TrumpRx Expands Discount Drug Access With 600 Generic Medications 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
NIH Infectious Disease Leadership Shake-Up Raises Concerns Amid Ebola, Hantavirus Outbreaks 
Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations 
US-Backed Pediatric HIV Treatment Drops After Foreign Aid Changes, Study Finds 
ADNOC Gas Targets Up to $4B Profit in 2026 
CDC Expands Ebola Screening Efforts at U.S. Entry Points Amid Congo and Uganda Outbreak 
Shein Scales Back Vietnam Operations as US Trade Rules Shift 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Novo Nordisk shares plunged more than 10% in mid-morning trading in Copenhagen on Monday after the pharmaceutical giant announced that its experimental obesity drug, CagriSema, failed to meet a primary endpoint in a closely watched clinical trial. The update intensifies competition in the rapidly expanding weight loss drug market, where Novo Nordisk faces mounting pressure from rival Eli Lilly.
The 84-week open-label head-to-head study was designed to demonstrate that CagriSema was non-inferior to Eli Lilly’s blockbuster obesity treatment, Tirzepatide, in reducing body weight. According to Novo Nordisk, patients treated with CagriSema achieved an average weight loss of 23%, while those receiving Tirzepatide recorded a superior 25.5% reduction. As a result, the trial did not meet its primary objective of proving that CagriSema was not lagging behind Tirzepatide in weight loss efficacy.
The disappointing trial results sent Novo Nordisk stock sharply lower, adding to a challenging year for the Danish drugmaker. In 2025, Novo shares have fallen by 49%, reflecting investor concerns over intensifying competition and shifting dynamics in the obesity treatment sector. The company previously secured a dominant position with its blockbuster drugs Wegovy and Ozempic, both of which fueled significant growth amid surging global demand for weight management medications.
However, competition has grown fiercer, particularly from Eli Lilly, whose Tirzepatide has gained significant traction. Additionally, telehealth providers offering lower-cost compounded alternatives have further pressured pricing and market share.
Despite the setback, Novo Nordisk confirmed that CagriSema was submitted to the U.S. Food and Drug Administration (FDA) for approval in December, with a regulatory decision expected by late 2026. The company recently announced board-level changes, including the appointment of industry veterans and Lars Rebien Sorensen as chairman, signaling a strategic push to strengthen leadership and respond more aggressively to U.S. market challenges.
Investors will now closely monitor regulatory developments and Novo Nordisk’s strategy to defend its position in the booming obesity drug market.
